The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Caspofungin, micafungin and anidulafungin are three drugs of the echinocandin class of antifungals available for intravenous treatment of invasive candidiasis and aspergillosis. They exhibit high in vitro and in vivo activities against Candida spp. and Aspergillus spp. In various clinical studies investigating candidemia and invasive candidiasis, Candida esophagitis, and fever in neutropenia, the clinical efficacy of the echinocandin tested was similar to that of established antifungals. Antifungal activity against strains no longer susceptible to conventional antifungal agents, such as fluconazole and amphotericin B suggests that echinocandins can be used as salvage therapy in life-threatening fungal infections. There is no cross-resistance to other antifungals. Excellent safety and tolerability of treatment with caspofungin has been documented over a total of 4.3 million patient days. Echinocandins are poor substrates of the cytochrome P450 enzyme family and can be safely co-administered with most drugs without the need for dosage adaptation. No dose reduction is required in renal impairment. A reduction in the daily maintenance dose has been recommended for caspofungin, but not for micafungin and anidulafungin in patients presenting with mild to moderate hepatic failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Increasing infections with opportunistic fungal organisms are the result of improved survival of patients in the intensive care unit, increasing catheterization and more aggressive immunosuppression. Candidiasis and aspergillosis are the most frequent nosocomial and community-acquired fungal infections [”
BackgroundVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“Unlike other classes of antifungal drugs, which act on fungal cell membranes, echinocandins inhibit fungal cell wall synthesis. Thus, cross-resistance between echinocandins and conventional antimycotics is not expected to occur. A further advantage of echinocandin antifungals is the lack of toxicity to mammalian tissu…”
BackgroundEffects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Douglas, C. M., Foor, F., Marrinan, J. A., Morin, N., Nielsen, J. B., Dahl, A. M., Mazur, P., Baginsky, W., Li, W., & el-Sherbeini, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12907 · Cited by 401
Fungal ß(1,3)-D-glucan synthesis
Douglas, C. M. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.55.66 · Cited by 312
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303 · cited 1×
“Results of in vitro studies on the susceptibility of A. fumigatus to selective echinocandins [”
BackgroundAspergillus fumigatus cell wall: composition and biosynthesis
Bernard, M., & Latgé, J.-P. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.9.17 · Cited by 282
Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254
Glucan Synthase Complex of Aspergillus fumigatus
Beauvais, A., Bruneau, J. M., Mol, P. C., Buitrago, M. J., Legrand, R., & Latgé, J. P. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.7.2273-2279.2001 · Cited by 209 · cited 1×
“Orthologs, i.e. genes of different species which evolved from a common ancestral gene, of FKS1 and FKS2 and theirgene products, Fks1p and Fks2p, have been detected in all fungal families studied to date, including strains of Aspergillus [”
BackgroundThompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., & Kurtz, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.2.444-453.1999 · Cited by 196
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Del Poeta, M., Cruz, M. C., Cardenas, M. E., Perfect, J. R., & Heitman, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.739-746.2000 · Cited by 169 · cited 1×
“Echinocandins are inactive against C. neoformans in vitro. A possible explanation for this, is the structural variation in the single copy, catalytic subunit of the β-(1,3)-glucan synthase in this fungus, resulting in diminished binding of the inhibitor molecules. The calcineurin inhibitor tacrolimus has been shown to…”
BackgroundSafety and tolerability of caspofungin acetate in the treatment of fungal infections
Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.01004.x · Cited by 148
Ikeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.614-618.2000 · Cited by 147 · cited 1×
“Micafungin at doses of 0.125 mg/kg body weight exhibited an efficacy inferior to that of amphotericin B but superior to that of fluconazole in prolonging the survival in animals infected with fluconazole-resistant C. albican s. The efficacy in reducing fungal counts was comparable to that of amphotericin B and superio…”
ResultInfluentialThe yeast cell-wall salvage pathway
Popolo, L., Gualtieri, T., & Ragni, E. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.111.121 · Cited by 142
Efficacy of Caspofungin in the Treatment of Esophageal Candidiasis Resistant to Fluconazole
Kartsonis, N., DiNubile, M. J., Bartizal, K., Hicks, P. S., Ryan, D., & Sable, C. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200210010-00009 · Cited by 77
Cited by
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“, and favourable pharmacokinetics, treatment outcomes in patients with IFIs treated with echinocandins remain less than optimal.([14,15,21]) As such, the need to optimize antifungal dosing and administration by exploiting Comparison of Echinocandin Antifungal Drugs 23”
BackgroundMethodNett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Metadata
- Authors
- Wagner, C., Graninger, W., Presterl, E., & Joukhadar, C.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 78
- Issue
- 4
- Pages
- 161-177
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W1970700571
- Cited by
- 125
- References
- 19
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.